The goal of this clinical trial is to Evaluating Metformin Efficacy and Safety when Co-administered with Antiepileptic Drugs in Patients with Seizures. The main question it aims to answer is:

• Does metformin have beneficial effect on epileptic patients?
• How metformin can affect epileptic patient's health?

Participants will be divided into 2 groups (control group and treatment group)

• Control group will receive standard treatment (levetiracetam &/or sodium valproate).
• Treatment group will receive standard treatment (levetiracetam &/or sodium valproate) + metformin

Inclusion Criteria:

• Age: 18 - 65 years old
• Obese and overweight patients with body mass index (BMI) ≥ 25.
• Diabetic & non diabetic patients.

Exclusion Criteria:

• Patients with severe liver damage or kidney disease (eGFR below 45mL/min/1.73 m²).
• Patients having acute or chronic disease which may cause tissue hypoxia and increase the risk of lactic acidosis (e.g. cardiac/respiratory failure, recent myocardial infarction).
• Patients who are already taking metformin.
• Cancer patients.
• Pregnant or lactating women.
• Patients with known hypersensitivity to the drug.